Company Encyclopedia
View More
name
Kamada
KMDA.US
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.
1.946 T
KMDA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking39/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.86%B
    • Profit Margin11.70%B
    • Gross Margin42.04%B
  • Growth ScoreB
    • Revenue YoY10.36%B
    • Net Profit YoY30.12%B
    • Total Assets YoY7.40%B
    • Net Assets YoY3.90%C
  • Cash ScoreB
    • Cash Flow Margin854.95%B
    • OCF YoY10.36%B
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreB
    • Gearing Ratio29.69%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kamada Ltd. Amends Shareholder Meeting Notice and Voting Procedures

    Kamada Ltd. has amended its proxy statement for the Annual General Meeting on December 10, 2025, addressing EMDA's comments. The amendments update the Articles of Association to align with current practices and laws, including changes to meeting notice requirements, succession procedures, voting procedures, and urgent Board meeting provisions. This information was published via EDGAR by Kamada Ltd. on December 02, 2025.

    Reuters·
    US
    KMDA
    +0.28%
    Reuters·
    US
    KMDA
    +0.28%

    FY2025 Earnings Estimate for Kamada Issued By HC Wainwright

    HC Wainwright analysts reduced their FY2025 earnings per share estimates for Kamada Ltd. from $0.47 to $0.38. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. Kamada's Q4 2025 earnings are estimated at $0.10 EPS. Kamada's stock has an average rating of 'Moderate Buy' with a consensus price target of $13.00. The company has a market cap of $418.64 million and a P/E ratio of 21.41. Institutional investors hold 20.38% of the stock.

    Market Beat·
    US
    KMDA
    +0.28%
    Market Beat·
    US
    KMDA
    +0.28%

    Kamada’s Growth Potential and Strategic Development Justify Buy Rating

    Analyst Andrew Fein of H.C. Wainwright has maintained a Buy rating on Kamada with a price target of $11.00, citing the company's growth potential and strategic development. Key factors include anticipated interim Phase 3 data from the inhaled AAT program and management's efforts to expedite trial enrollment. Kamada's focus on expanding plasma collection centers and pursuing business development opportunities is expected to enhance its market portfolio. Recent financial performance shows increased revenues and adjusted EBITDA, supporting the Buy rating.

    Tip Ranks·
    US
    KMDA
    +0.28%
    Tip Ranks·
    US
    KMDA
    +0.28%

    Kamada Ltd. Reports Strong Growth Amid Challenges

    Kamada Ltd. reported strong Q3 earnings, with total revenues of $135.8 million for the first nine months of 2025, an 11% increase year-over-year. Adjusted EBITDA rose 35% to $34.2 million. The company launched new biosimilar products and expanded plasma collection with FDA approvals. However, challenges include declining Glacia royalties, below-plan Cytogam sales, and slow clinical trial enrollment. Kamada maintains its annual revenue guidance of $178-$182 million and plans to drive growth through commercial expansion and M&A activities. Overall, the outlook remains positive despite existing hurdles.

    Tip Ranks·
    US
    KMDA
    +0.28%
    Tip Ranks·
    US
    KMDA
    +0.28%

    Kamada Ltd. Reports Strong Q3 2025 Financial Results with 30% Profit Growth

    Kamada Ltd. reported strong Q3 2025 financial results, achieving a 13% year-over-year revenue growth to $47 million and a 34% increase in adjusted EBITDA. For the first nine months, revenues rose by 11% to $135.8 million. The company maintains a positive outlook, reiterating full-year revenue guidance of $178 million to $182 million. Kamada is advancing clinical trials and expanding plasma collection operations, including FDA approval for its Houston facility. Analysts rate (IL:KMDA) stock as a Buy with a price target of ILs2519.00.

    Tip Ranks·
    US
    KMDA
    +0.28%
    Tip Ranks·
    US
    KMDA
    +0.28%
    © 2025 Longbridge｜Disclaimer